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Abstract
Rheumatoid arthritis is a chronic inflammatory disease affecting approximately 1% of the population and is characterized by
cartilage and bone destruction ultimately leading to loss of joint function. Early detection and intervention of disease
provides the best hope for successful treatment and preservation of joint mobility and function. Reliable and non-invasive
techniques that accurately measure arthritic disease onset and progression are lacking. We recently developed a novel
agent, SapC-DOPS, which is composed of the membrane-associated lysosomal protein saposin C (SapC) incorporated into
1,2-dioleoyl-sn-glycero-3-phospho-L-serine (DOPS) lipid nanovesicles. SapC-DOPS has a high fusogenic affinity for
phosphatidylserine-enriched microdomains on surfaces of target cell membranes. Incorporation of a far-red fluorophore,
CellVue Maroon (CVM), into the nanovesicles allows for in vivo non-invasive visualization of the agent in targeted tissue.
Given that phosphatidylserine is present only on the inner leaflet of healthy plasma membranes but is ‘‘flipped’’ to the outer
leaflet upon cell damage, we hypothesized that SapC-DOPS would target tissue damage associated with inflammatory
arthritis due to local surface-exposure of phosphatidylserine. Optical imaging with SapC-DOPS-CVM in two distinct models
of arthritis, serum-transfer arthritis (e.g., K/BxN) and collagen-induced arthritis (CIA) revealed robust SapC-DOPS-CVM
specific localization to arthritic paws and joints in live animals. Importantly, intensity of localized fluorescent signal
correlated with macroscopic arthritic disease severity and increased with disease progression. Flow cytometry of cells
extracted from arthritic joints demonstrated that SapC-DOPS-CVM localized to an average of 7–8% of total joint cells and
primarily to CD11b+Gr-1+ cells. Results from the current studies strongly support the application of SapC-DOPS-CVM for
advanced clinical and research applications including: detecting early arthritis onset, assessing disease progression real-time
in live subjects, and providing novel information regarding cell types that may mediate arthritis progression within joints.
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Introduction
Rheumatoid arthritis (RA) is a chronic inflammatory disease
that affects 1% of the population. RA is manifested as chronic
inflammation leading to severe pain and loss of mobility. If
unchecked, disease culminates in destruction of joint tissue, loss of
function, and a profound reduction in quality of life. Several
effective biologics have been developed over the last decade that
limit arthritis progression for a large percentage of RA patients,
and in a number of cases, achieved remission. These therapies are
most effective when used to intervene early in the RA disease
process; however, reliable and manageable tools for evaluation of
early joint inflammation and disease remission in response to
therapeutics are lacking. Recently, new guidelines put forth by the
American College of Rheumatology (ACR) and The European
League Against Rheumatism (EULAR) outlined standard assess-
ments of measuring clinical outcomes, which are needed both for
clinical practice and clinical trials [1]. These proposed definitions
of RA remission do not include imaging results but do indicate an
association with slowing of radiographic progression as residual
synovitis may exist in many patients whose disease appears
inactive based on conventional clinical evaluation. While radio-
graphic progression can assess joint damage, soft tissue inflam-
mation and destruction are not readily detected by radiography.
PLoS ONE | www.plosone.org 1 March 2012 | Volume 7 | Issue 3 | e33966A consensus has not been established regarding assessment of
arthritic events involving inflammatory soft tissue with regards to
imaging methods due in part, to the absence of a reliable,
quantitative methodology.
Joint counts are part of the ACR and EULAR proposed criteria,
and an essential part of the clinical component of assessing
rheumatic disease. However, several studies have suggested that
differences in joint counts do not necessarily correlate with clinical
outcomes (reviewed in [2]). Thus, an objective and quantifiable
clinical parameter that correlates with joint damage and
inflammation would be highly valuable to the clinic, and imaging
has been proposed as a means to provide this missing vital
information. Several imaging methods are currently in use for the
assessment of joint damage, including X-ray, magnetic resonance
imaging (MRI), ultrasound, and X-ray computed tomography [3–
6]. For clinical ease, X-rays have been the standard for assessment
of joint damage progression, which is estimated by joint space
narrowing and erosions [7]. Multiple quantitative assessment
methods for evaluating radiographic damage have been proposed
[6]. While bone structures are readily visible by x-ray, soft tissue
inflammation and destruction, which are associated with early
stages of RA, are not readily detected. Both magnetic resonance
imaging (MRI) and ultrasound have been looked to for assessment
of early joint damage. MRI can provide superior imaging of soft
tissues and edema, as compared to conventional x-ray, but is time-
consuming, expensive and not readily available to many clinicians.
Ultrasound can also provide information regarding soft tissue
damage and cartilage and bone destruction; however, while
ultrasound may be easier to access in the clinic than MRI, training
of personnel, reproducibility and joint accessibility remain as
significant challenges for bringing this imaging modality to the
clinic.
Optical imaging is a relatively new imaging modality and
provides great promise for analyzing events occurring early in the
pathogenesis of arthritis (reviewed in [8,9]). Optical imaging uses
far-red and near-infrared (600–1000 nm range) [10,11] molecular
or nanoparticle probes that when excited emit light that can
penetrate the skin more readily than probes with lower emission
wavelengths, facilitating signal detection in vivo. Advantages of
optical imaging include (1) the decrease in exposure to radiation as
compared to X-ray (2) the clear targeting and localization of
molecular probes associated with disease pathogenesis and (3)
minimal acquisition time.
Targeting of damaged tissue to enhance imaging of inflamma-
tion in arthritis could provide a valuable tool for the early
assessment of disease and for the progression of disease. In the
current study, we have characterized the targeting of novel
nanovesicles composed of 1,2-Dioleoyl-sn-Glycero-3-Phospho-L-
Serine (DOPS) and a fusogenic protein, saposin C (SapC) to image
arthritic joints. SapC associates with phosphatidylserine (PS) on
cell membranes by embedding amino and carboxyl-end amphi-
pathic helices into the outer leaflet of membranes [12]. PS
becomes exposed on the outer membrane of cells that are
damaged or undergoing apoptosis. Since SapC-DOPS engages
cell membranes with exposed PS, we hypothesized that SapC-
DOPS may localize to cells involved in inflammation/injury in
arthritis.
The current study determines the signal distribution in mice of
SapC-DOPS labeled with a far-red fluorophore, CellVueH
Maroon (CVM), as assessed by optical imaging in two arthritis
mouse models that each exhibit different disease courses and
etiology. Furthermore, the intensity of SapC-DOPS signal as
compared with arthritic severity over the course of disease was
determined and cell types within joints that are targeted by
SapC-DOPS were investigated. Our results suggest that SapC-
DOPS localizes specifically to cells involved in early inflammatory
stages of arthritis and that this novel agent has potential use as an
imaging agent for inflammatory arthritis.
Materials and Methods
Animal Use
Ethics statement. All experiments involving mice complied
with National Institutes of Health guidelines. The protocol was
approved by the Institutional Animal Care and Use Committee of
the Cincinnati Children’s Hospital Research Foundation (Animal
Welfare Assurance Number A3108-01).
Collagen-induced arthritis (CIA)
DBA/1J male mice eight weeks of age were injected
intradermally at the base of the tail with 100 mg of bovine type
II collagen (CII) (Elastin Products Co., Inc.) in complete Freund’s
adjuvant (CFA) on day 1 and given a similar challenge once again
21 days following the initial CII injection, as previously described
[13,14]. Mice were evaluated for macroscopic arthritis using an
arthritic index macroscopic scoring system ranging from 0 to 4
(0=no detectable arthritis, 1=swelling and/or redness of paw or
one digit, 2=two joints involved, 3=three joints involved and
4=severe arthritis of the entire paw and digit).
K/BxN arthritis
Sera were collected from KRN6NOD F1 mice, and 150 ml was
given by intraperitoneal injection to C57Bl/6J mice at day 0 of
disease. Calipers were used to measure paw thickness and mouse
ankle thickness. For ankle thickness, elliptical area of mouse ankles
was calculated using intermalleolar measurements and measure-
ment of the area between the dorsal talus and calcaneus.
IVISH live imaging of SapC-DOPS-CVM
An aliquot of CellVueH Maroon (CVM, Molecular Targeting
Technologies Inc., West Chester, PA) in ethanol was mixed with
phospholipid solvent for bath sonication preparation by the
procedure as previously described [15,16]. CVM-labeled SapC-
DOPS nanovesicles were separated from free CVM dye using a
Sephadex
TM G25 column (PD-10, Amersham Pharmacia Biotech,
Piscataway, NJ). CVM-labeled SapC-DOPS (SapC=4.2 mg/kg,
DOPS=2 mg/kg, CVM=6 mmol) and control agents were
administered i.p. or by tail vein injection in a 200 microliter
volume into animals. Real-time live images were taken using an
IVIS 200 Series imaging system with an XFO-6 fluorescent kit and
quantified using Living Image software (Xenogen, Alameda, CA).
Average radiance values (IVISH intensity) of designated elliptical
areas of the front and hind paws were determined and the mean
values between groups compared.
Flow Cytometry
For joint cell analysis, mice were sacrificed, paws were removed
above the ankle joint, skin was dissected away and the remaining
tissue was placed in 0.5 ml of RPMI. Using a number 10 scalpel
blade and forceps, tissue was separated from bones and joints and
dissected/shredded as previously described [17]. Crude cell
suspensions were strained through a 70 micron cell strainer and
cells counted. 1610
6 cells were stained in 100 ul of FACS buffer
(1XPBS, 0.2%BSA) containing 10 ul of 2.4G2 (American Type
Culture Collection) hybridoma supernatant. Three antibody
panels were assessed for cells from CIA treated mice as follows:
panel 1=anti-CD4-FITC (clone GK1.5, BD Pharmingen, San
Jose, CA), anti-CD8-Pacific Blue (clone 53-6.7, BD Pharmingen,)
SapC-DOPS Agents for Imaging in Arthritis
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CD11b-FITC (clone M1/70, BD Pharmingen), anti-CD11c-PE
(clone HL3, BD Pharmingen), anti-Gr-1-AF700 (clone RB6-8C5,
BD Pharmingen), and anti-F4/80-E450 (clone BM8, eBioscience);
Panel 3=anti-CD31-FITC (clone 390, BD Pharmingen) and anti-
CD55-PE (clone RIKO-5, BD Pharmingen). Three antibody
panels were assessed for cells from K/BxN treated mice as follows
(clones as above): panel 1=anti-CD4-FITC, anti-CD8-Pacific
Blue and anti-CD19-PE; Panel 2=anti-CD11b-FITC, anti-
CD11c-PE, and anti-Gr-1-E450; Panel 3=anti-CD31-FITC,
anti-CD55-PE and anti-F4/80-E450. Cells were acquired using
a FACSCanto I RUO analytical cytometer and analyzed using
FACSDiva software (Becton Dickinson, San Jose, CA).
Statistical analysis
Correlation was analyzed using Pearson Product Moment
Correlation and Spearman Rank Order Correlation. Unpaired
Students t-test was used to compare normally distributed
parametric data between groups. Mann Whitney was used to
compare nonparametric data between groups.
Results
SapC-DOPS localizes and accumulates for visualization of
arthritic joints by fluorometric imaging in K/BxN and CIA
arthritis models
To test the hypothesis that the PS targeting agent SapC-DOPS
localizes to joint tissue following local destructive inflammatory
events, the uptake of SapC-DOPS labeled with CVM (SapC-
DOPS-CVM) was measured by optical imaging of mice
challenged with two established models of inflammatory joint
disease, each with distinct etiologies. First, mice challenged with
K/BxN serum-transfer arthritis were examined seven days
following sera injection. Mice were given SapC-DOPS-CVM
and exhibited robust CVM fluorescence in macroscopically
arthritic paws as compared to arthritic paws in mice not given
SapC-DOPS-CVM (Figure 1A). Mice not treated with sera did
not develop arthritis and correspondingly did not exhibit
detectable CVM signal. In Figure 1B, mice challenged with K/
BxN sera and receiving DOPS-CVM alone without SapC
conjugation did not exhibit detectable signal, although arthritis
was macroscopically apparent, demonstrating that SapC conju-
gation to DOPS-CVM is required for localization of CVM signal
to arthritic paws. Administration of CVM alone also resulted in no
detectable signal (data not shown).
SapC-DOPS-CVM targeting of arthritic tissue was further
assessed by examining localization in mice challenged with CIA,
one of the most well-characterized of the murine models of
inflammatory joint disease. A cohort of DBA/1J mice was
challenged, and as expected, macroscopic disease was apparent
at 28 days following primary CII injection. Mice exhibiting
macroscopically apparent arthritis also displayed localization of
SapC-DOPS-CVM accumulation as determined by IVISH
imaging specifically in macroscopically arthritic, but not non-
arthritic paws 28 days following primary CII injection (Figure 2).
In mice that did not receive CII (Controls, Figures 2A and 2B)
SapC-DOPS-CVM IVISH signal was not detected. Furthermore,
images focused on paws with arthritic digits (Figures 2C–2F)
indicated that SapC-DOPS-CVM selectively accumulated to high
levels in individual digits of a paw that were swollen, but not to
those that were free of macroscopic evidence of disease, as shown
by the swollen ankle and digit depicted in Figures 2C and 2D and
in the forepaw digits shown in Figures 2E and 2F. Signal was also
detected in knees (Figure 2B) from challenged mice as compared to
control mice (no CII). While knee joints are not accessible for
clinical scoring, further analysis of shaven mouse knees at day 28
following CII injection indicated that increased SapC-DOPS-
CVM fluorescence was associated with arthritic knee joint
histopathology. Figure 2G is representative of mouse knees that
did not exhibit SapC-DOPS-CVM uptake (fluorescence) with little
arthritic knee joint pathology (Figure 2H) including a small
amount of infiltrating inflammatory cells and limited synovial
hyperplasia. Figure 2I is representative of increased uptake of
SapC-DOPS-CVM in mouse knees with marked arthritic
pathology (Figure 2J) including abundant infiltration of inflam-
matory cells and synovial hyperplasia.
SapC-DOPS targeting of arthritic joints over the course of
disease correlates with disease severity
Given that SapC-DOPS targets macroscopically apparent
arthritic joints, it was of great interest to determine the kinetics
of SapC-DOPS accumulation during the course of arthritic
disease. Determination of SapC-DOPS-CVM localization over
time provides information as to whether the intensity of signal
correlates with the severity of disease. Since both the K/BxN and
CIA models of inflammatory joint disease exhibit distinct etiologies
and unique time courses of disease initiation and progression,
SapC-DOPS uptake and accumulation was assessed over time in
both models beginning with disease initiation and continuing
Figure 1. SapC-DOPS-CVM localizes to arthritic joints and is
visible by live fluorometric imaging. Male C57Bl/6 mice three
months of age were given 150 ml of sera i.p. as indicated. Seven days
after sera injection, mice were imaged by IVISH (A) five hours following
SapC-DOPS-CVM i.v. injection as indicated (- is PBS); (B) two hours
following i.v. injection of DOPS-CVM, DOPS-CVM plus uncoupled SapC,
or SapC-DOPS-CVM as indicated. Arrows indicate macroscopically
swollen paws.
doi:10.1371/journal.pone.0033966.g001
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administered to C57Bl/6 mice and animals were imaged by IVISH
six hours later and then daily. SapC-DOPS-CVM was adminis-
tered every other day, beginning at the initial sera administration.
Average radiance values (IVISH intensity) of designated elliptical
areas of the hind paws were determined and the mean values of
groups for each day are indicated in Figure 3A. In K/BxN sera-
challenged mice injected with SapC-DOPS-CVM, steady and
significant increases were observed in intensity of CVM signal as
shown in Figure 3A, with highest intensity at day 8 following K/
BxN sera administration. As expected, control mice receiving K/
BxN sera but no SapC-DOPS-CVM had low CVM signal
(background radiance) that did not change throughout the analysis
period despite robust arthritic disease development. Control mice
receiving SapC-DOPS-CVM every other day but not K/BxN
sera, showed a slow increase in fluorescent signal intensity,
indicating that with multiple injections of agent a marginal
background accumulation of the agent within the paws exists that
quickly plateaued. Consistent with our hypothesis that SapC-
DOPS-CVM targeting would correlate with disease severity, paws
exhibiting higher positive changes in paw thickness (Figure 3B)
and ankle circumference (Figure 3C) as measurements of arthritic
severity concurrently exhibited higher levels of SapC-DOPS-
CVM localization as indicated by IVISH intensity. These data
suggest that increases in arthritic severity as assessed by
quantitative clinical arthritic measurements significantly correlate
with increases in localization of SapC-DOPS to arthritic joints in
the K/BxN model of arthritis.
In parallel analyses, CII-challenged mice were given SapC-
DOPS-CVM at day 23 and every other day thereafter, and
imaged daily from days 24–34 following CII primary immuniza-
tion (Figure 4A). Similar to results in the K/BxN model, paws
from mice immunized with CII and injected with SapC-DOPS-
CVM showed prominent CVM signal at day 28 that steadily
increased over the course of disease. Similar to the K/BxN
arthritis experiments, the repetitive SapC-DOPS-CVM treatment
regime resulted in low-level accumulation of SapC-DOPS-CVM
signal in paws of mice receiving SapC-DOPS-CVM alone,
without CII treatment, indicating background accumulation of
the agent that was independent of disease pathogenesis. As
expected fluorescent signal was not observed in paws of either
control or arthritic mice that did not receive SapC-DOPS-CVM.
Of note, paws from CIA-challenged mice, which received SapC-
DOPS-CVM that were overtly macroscopically arthritic had the
highest fluorescent intensity, and arthritic scores showed a positive
correlation with increases in CVM intensity (Figure 4B). Perhaps
an even more significant observation was that paws from CIA-
challenged mice, which were macroscopically scored as non-
arthritic, also showed significant increases in CVM fluorescence
intensity as compared to control mice (not treated with CII)
(Figure 4A). This observation suggests that SapC-DOPS-CVM
may localize to joints with subclinical arthritis.
SapC-DOPS-CVM is detectable in joint cell suspensions
and accumulates primarily in CD11b+ Gr-1+ cells from K/
BxN and CIA arthritic joints
Since SapC-DOPS-CVM localizes specifically to arthritic joints,
it was of great interest to determine cell types targeted by SapC-
DOPS-CVM in both the K/BxN and CIA arthritis models. Cells
extracted from joints were stained with labeled antibodies to cell-
surface markers on lymphocytes (T cells: CD4, CD8; B cells:
CD19), myeloid cells (CD11b, CD11c, Gr-1 and F4/80),
endothelial cells (CD31), and synovial fibroblasts (CD55
high)
[18]. For K/BxN, at day nine following sera administration, mice
were sacrificed and single cell suspensions were obtained from
back paws of individual mice. Analysis of joint cells from mice
treated with SapC-DOPS-CVM shows an increase in the CVM+
joint cells upon sera treatment (Figure 5A and 5B). Figure 5B
indicates an average of ,6–7% of the isolated live-gated joint cells
were positive for CVM as opposed to only 1% of the cells staining
positive for CVM in the no KBxN sera negative control. In
Figure 5C the majority of cells to which CVM localizes also
stained positively for the myeloid markers Gr-1 (mean=1.9%,
ranging from 0.2%–4.5%) and CD11b (mean=2.8%, ranging
from 1.1%–6.0%). Further analysis of the 6–7% SapC-DOPS-
CVM positive cells for co-expression of cell surface markers
indicates that approximately one-third express both CD11b and
Gr-1 (mean=1.7%, ranging from 0.5%–3.2) (Figure 5D and 5E),
which is consistent with a neutrophil phenotype. None of the
CVM+ cells stained positive for both Gr-1 and CD11c.
Additionally, the expression of CD19, CD31 and CD55 in
SapC-DOPS-CVM+ cells trended to be higher in joint cells from
mice treated with K/BxN sera as compared to joint cells from the
control mice (Figure 5C).
For CIA, back paws were taken and joint cells pooled for
analysis. Mice were sacrificed at 35 days following primary CII
injection. Arthritic macroscopic scores were variable among the
mice as would be expected for CIA with a median score of 1.5–2
Figure 2. SapC-DOPS-CVM localizes to arthritic joints in CIA.
(A) Light images of DBA/1 mice treated with CII (left, CIA) and non-CII
treated (right, Control). (B) IVISH images of mice in A, 48 hours following
SapC-DOPS-CVM i.v injection. Light images of CIA hind paw (C) and
forepaw (E) with corresponding IVISH images in (D) and (F). Solid black
arrows indicate macroscopically swollen paws and white arrows
indicate macroscopically swollen joints. (G) and (I) IVISH images of CII-
treated mice 48 hours following SapC-DOPS-CVM i.v. injection, with
arrows indicating corresponding histological knee sections (H) and (J)
stained with hematoxylin and eosin. CVM intensity as measured by live
fluorometric imaging is represented by red, yellow, green, blue
colorimetric scale with red representing highest and blue representing
lowest intensity.
doi:10.1371/journal.pone.0033966.g002
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SapC-DOPS-CVM as a negative control. Disease incidence in the
SapC-DOPS-CVM treated mice and the control non SAPC-
DOPS-CVM treated animals was similar, with 63% (5/8 and 50%
(4/8 affected) with overt macroscopic disease, respectively. Similar
to the K/BxN mice, cells extracted from joints were stained with
labeled antibodies for lymphoid, myeloid, endothelial and synovial
fibroblast cells as described above. In Figure 6 joint cells from mice
treated with SapC-DOPS-CVM show an increase in CVM+ cells
upon CII challenge with the mean percent of CVM+ joint cells
averaging approximately 8% of live cells (Figure 6B). CII-
challenged mice showed populations that were positive for
CD19, CD11b, CD55 and Gr-1, regardless of SapC-DOPS-
CVM treatment by dot plot analysis (Figure 6A). However, the
majority of CVM+ cells from CIA mice and given SapC-DOPS-
CVM (CII, +CVM) were also positive primarily for CD11b
(mean=5.5%, range=0.5% to 24.3%) and Gr-1 (mean=4.8%,
range 0.3% to 24.2%) (Figure 6C). As observed for the K/BxN
joint cells, CVM+ populations also stained positive for CD19
(range 0.2% to 1.3%), CD31 (range 0.3% to 3.1%) or CD55
(range 0.3 to 0.9%). Figure 6D indicates the gating strategy for
CVM+ populations, which were further analyzed for dual
expression of specific cell surface markers. Similar to results with
joint cells from K/BxN-challenged mice, a significant portion
(mean=5.4%, ranging from 0.3% to 20%) of the SapC-DOPS-
CVM+ cells also expressed both CD11b and Gr-1 on their cell
surface, but not CD11c (Figure 6E) and CVM+ cells did not
stain positive for both Gr-1 and CD11c. The variability in
SapC-DOPS-CVM+ cell populations extracted from individual
mice is consistent with the variability in the penetrance of disease
as cells from both hind paws were pooled for cell analysis.
Discussion
The present studies investigate the utility and underlying
mechanism(s) of SapC-DOPS nanovesicles as an optical imaging
agent to detect tissue damage in inflammatory arthritic joints. In
two separate animal models of inflammatory arthritis, SapC-
DOPS labeled with the fluorophore CVM was visualized locally in
arthritic inflammatory joints. Furthermore, throughout the course
of both K/BxN and CIA inflammatory arthritis SapC-DOPS
intensity increased and correlated with increases in multiple
independent parameters of arthritic disease assessment. Joint cells
targeted by SapC-DOPS-CVM were primarily positive for both
CD11b and Gr-1—cell markers indicative of neutrophils—that
have previously been shown to be critical mediators of
inflammatory events in arthritis [19–22]. The use of SapC-DOPS
to target imaging agents to areas of joint inflammation provides a
potentially novel, noninvasive, and robust tool in the assessment of
inflammatory arthritis.
Optical imaging has great promise for use in inflammatory
arthritis, particularly in RA, in which the peripheral joints are the
most highly affected. Assessment of joint damage in RA has been
measured primarily through x-ray imaging analysis, which does
not readily provide information regarding the earliest local
pathogenic events (i.e., inflammation), which occur prior to joint
Figure 3. CVM signal intensity increases during the course of K/BxN arthritis and correlates with arthritic parameters. C57Bl/6 mice
were given 150 ml of K/BxN sera i.p. and 84 mg of SapC-DOPS-CVM as indicated. (A) Means of back paw intensity values are graphed as columns with
error bars representing standard error of the mean. * p,0.05, Students t-test, n$4 mice per group. For mice treated with K/BxN sera (n=7) and given
SapC-DOPS-CVM the (B) changes in paw thickness and (C) changes in ankle circumference were rounded to the nearest millimeter and the means
(+/2 SEM) of IVISH signal intensity for the corresponding paws are graphed as columns. Lines represent linear regression of values in B and C with
correlation coefficients indicated. Correlation of arthritis parameters and IVISH intensity signals in B and C is significant p,0.005, as determined by
Pearson Product Moment Correlation and Spearman Rank Order Correlation.
doi:10.1371/journal.pone.0033966.g003
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modalities to assess soft tissue damage; however, each of these
modalities has significant factors hindering their routine use in the
clinic. Optical imaging in humans has primarily involved imaging
of vasculature and lymphatics using the non-specific, near-infrared
dye indocyanine green [23], with more recent advances using
fluorescent-labeled folate receptor-alpha targets for tumor-specific,
fluorescence-assisted cytoreductive surgery [24]. For RA patients,
visualization of indocyanine green uptake focusing on the finger
and wrist joints has been demonstrated with newly developed
optical imaging instrumentation [25]. In animal models of
arthritis, anti-E-selectin labeled with a near-infrared fluorophore
demonstrated specificity for arthritic joints in CIA mice [26]. In
addition, antibody and folate receptor targets have been used to
image activated macrophages in arthritis models and other
inflammatory settings [27–29].
Using optical imaging our studies indicate that SapC-DOPS-
CVM appears to localize to arthritic joints. Our prior optical
imaging studies regarding tissue-specific distribution of SapC-
DOPS-CVM signal demonstrated fluorescent signal in only liver
and spleen of otherwise unchallenged nude mice that diminished
over time and was not detectable 48 hours following injection
[16]. Our present data indicate that in two separate models of
arthritis, SapC-DOPS-CVM is detected by optical imaging in
arthritic joints. Similar results were obtained in a third model of
arthritis in which chronic polyarthritis is driven solely by
overexpression of human TNF-alpha via a transgene [30].
SapC-DOPS-CVM was clearly localized to arthritic joints of
TNF-alpha transgenic mice but not to joints of littermate control
transgene negative animals (data not shown). Thus, this novel
compound appears to selectively target arthritic tissues, regardless
of disease etiology, giving it a monumental advantage over
imaging through the use of non-specific fluorophores.
SapC-DOPS-CVM localization as assessed by optical imaging
may be useful as a marker for both the detection of early pre-
clinical disease and for closely monitoring disease progression.
Analysis of SapC-DOPS-CVM accumulation in joints over the
course of both K/BxN and CIA arthritis indicated an increase in
CVM signal as arthritis progressed. A significant finding of the
present study is that clinical parameters, such as paw thickness and
Figure 4. CVM signal intensity from CII-challenged mice increases over disease course and correlates with arthritic severity. (A) Mice
were injected i.p. with SapC-DOPS-CVM starting on day 23 following primary CII immunization and then every other day. Mice were imaged daily by
IVISH. Columns indicate the mean IVISH intensity values (average radiance) for paws in each group +/2 the SEM. Mice were scored macroscopically
for arthritis daily. N of paws imaged in groups were as follows: No SapC-DOPS-CVM, CII+: 16; SapC-DOPS-CVM+, no CII:16; SapC-DOPS-
CVM+,CII+macroscopic arthritis: 8; SapC-DOPS-CVM+CII+ no macroscopic arthritis: 24. *=p,0.05 as compared to SapC-DOPS-CVM+, no CII, Mann
Whitney (B) Box plots indicate the median values and range for IVISH intensity of paws receiving the specified macroscopic arthritic score during the
time course of disease. The line represents linear regression of mean values with the correlation coefficients indicated. Correlation of arthritis
parameter values and IVISH intensity signal values is significant, p,0.005, Pearson Product Moment Correlation and Spearman Rank Order
Correlation.
doi:10.1371/journal.pone.0033966.g004
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correlations with CVM intensity (i.e., increased severity of disease
correlated with higher signal intensity). Non-sera treated mice that
received SapC-DOPS-CVM every other day, accumulated
significant low-level signal that plateaued early in disease. This
result indicates that such low level of fluorescent signal may
accumulate non-specifically due to the repeated administration of
the fluorescent agent but would not hinder detection of early
arthritic disease. While our studies focus on proof-of-principle for
assessing joint damage in a mouse model over time, in clinical
practice low level signal accumulation would not be expected since
multiple injections over a short period of time would not be
necessary. In parallel CIA analysis, signal intensity of SapC-
DOPS-CVM localization to paw joints also increased in CII-
challenged mice. In CII-treated mice, macroscopically arthritic
paws showed a significant correlation with increased CVM signal
intensity. Interestingly and specifically pertinent to early detection
of inflammation and disease, in CII challenged mice a limited
number of paw joints that were not overtly arthritic showed an
increase in CVM signal intensity, which we believe may represent
the earliest stages of arthritis. Future studies will histologically
assess microscopic arthritis over the time course of disease to
directly assess the histological changes that might be occurring
sub-clinically in these paws as related to SapC-DOPS-CVM
accumulation. Our results did not indicate any affects on arthritic
disease progression and severity as both K/BxN and CIA arthritic
disease progressed similarly to previous experiments performed in
our laboratory; however, the results of the current study do not
Figure 5. SapC -DOPS-CVM targets primarily CD11b+Gr-1+ joint cells in the K/BxN model of arthritis. Joint cells from hind paws were
stained with antibodies to cell surface markers as indicated. FACS plots are representative from one animal, with bar graphs indicating the means +/2
the SEM of groups. (A) Dot plots indicate cell populations that are CVM+ and positive for other cell surface markers as indicated. (B) CVM+ cells.
Columns represent mean of total cells that are CVM++ /2 SEM with treatment of animals as indicated. *=p,0.05. (C) Bar graph indicates means +/2
the SEM of the percentage of total cells that are CVM+ and positive for the indicated cell surface marker. *=p,0.05, Students t-test. (D) Dot plots
show forward (FSC) and side scatter (SSC) for joint populations with gating for CVM+ cell populations versus side scatter (SSC). Gated CVM+ cells are
further analyzed for specific cell-surface markers CD11b, CD11c and Gr-1 with percentages indicated. (E) Columns represent the mean +/2 the SEM of
the percentage of total cells that are positive for CVM, CD11b, and also positive for either CD11c or Gr-1 *=p,0.05. N=4 No Sera, SapC-DOPS-CVM;
N=9 Sera, SapC-DOPS-CVM.
doi:10.1371/journal.pone.0033966.g005
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kinetics and severity of arthritic disease.
Analysis of SapC-DOPS-CVM targeted cells extracted from
arthritic joints indicates that the main cell type targeted is CD11b
and Gr-1 positive. Mature granulocytes, particularly neutrophils
that reside in tissues, express Gr-1 on their cell surface [31,32].
Neutrophils are short-lived cells that are involved in innate
immunity and host defense but have also been shown to be
involved in mechanisms that drive RA [19–22,33]. Deficits in the
ability of neutrophils to undergo apoptosis have been associated
with autoimmune disorders including RA [34]. Disruptions in
neutrophil activation mechanisms (i.e., degranulation, oxidative
burst) have been shown to limit the local tissue damage commonly
associated with inflammatory joint disease [35,36]. Neutrophil
activation with production of reactive oxygen species leads to
phospholipid oxidation and subsequent externalization of PS [37].
Neutrophils are one of the most abundant cell types in synovial
fluid from RA patients and products of neutrophil activation are
present in RA synovial fluid as well [38]. Thus, SapC-DOPS
targeting of this cell type is not surprising, as activated neutrophils
readily externalize PS. Furthermore, the resistance of neutrophils
to apoptosis in RA, potentiates the usefulness of SapC-DOPS
binding as a clinical measure. A large portion of targeted cells did
not stain positive for CD11b or Gr-1, indicating that other cell
types are also targeted by SapC-DOPS-CVM, and future studies
with more extensive cell markers will reveal additional targeted cell
types. However, other cell types targeted by SapC-DOPS-CVM
within our studies include CD19+ cells, which is a B-cell marker;
CD31, a marker for endothelial cells; and CD55, a marker that is
expressed at high levels on synovial fibroblasts [18]. All of these
cells are involved in the early inflammatory stages of arthritic
disease, providing further support for use of this agent in early
detection of inflammatory joint disease [39–46].
A significant finding from these studies was that SapC-DOPS is
able to target arthritic joints in multiple disease models that exhibit
distinct etiologies [47,48]. The targeting of SapC-DOPS correlat-
Figure 6. SapC -DOPS-CVM targets primarily CD11b+Gr-1+ joint cells in the CIA model of arthritis. Cells were stained with antibodies to
cell surface markers as indicated. FACS plots are representative from one animal, with bar graphs indicating the means +/2 the SEM of groups. (A)
Dot plots indicate cell populations from mice treated as indicated that are CVM+ and positive for other cell surface markers as indicated on left. (B)
CVM+ cells. Columns represent mean of total cells that are CVM++ /2 SEM (error bars) with treatment of animals as indicated. * p,0.0001 Mann
Whitney. (C) Columns indicate means +/2 the SEM (error bars) of the percentage of total cells that are CVM + and positive for the indicated cell
surface marker. *=p,0.05 Mann Whitney. (D) Dot plots show forward (FSC) and side scatter (SSC) for joint populations with gating for CVM +cell
populations versus side scatter (SSC). Gated CVM + cells are further analyzed for combinations of the specific cell-surface markers CD11b, CD11c and
Gr-1 as indicated. (E) Columns represent the mean +/2 the SEM (error bars) of the percentage of total cells that are positive for CVM, CD11b, and also
positive for either CD11c or Gr-1. N=4, No CII, SapC-DOPS-CVM; 8, CII+, SapC-DOPS-CVM+ *p ,0.05, Mann Whitney.
doi:10.1371/journal.pone.0033966.g006
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arthritis models. In K/BxN mice 100% penetrance of hind paws is
normally observed by day 8 of disease. Our data indicated a clear
targeting of SapC-DOPS-CVM to hind paws in K/BxN arthritis
over the time course of disease and a direct correlation with paw
thickness and ankle circumference. In addition, joint cells taken at
day 8 of disease showed SapC-DOPS targeting of CD11b+Gr-1+
cells, which is consistent with a neutrophil phenotype. Neutrophils
have been implicated as a major driver of pathogenesis in the K/
BxN arthritis model [40,49]. For CIA, disease incidence is slightly
less with ,50–100% of mice developing overt macroscopic disease
with both distal (i.e., paw joints) and proximal (i.e., knees) joint
involvement that is not uniform, similar to the sporadic joint
involvement exhibited by RA patients. In contrast with the K/
BxN model in which disease appears quickly, macroscopic signs of
arthritis in CIA can become apparent weeks following the
secondary collagen immunization [50]. In addition, the higher
degree of variability observed in the analysis of cell types targeted
by SapC-DOPS in the CIA model are likely reflective of both the
variability and time course of joint involvement in the CIA model.
Given the more complex disease process of CIA [46], SapC-
DOPS is likely targeting multiple cell types involved in the
pathogenesis of arthritis. Nevertheless, the significant correlation
between SapC-DOPS-CVM intensity and arthritic severity
observed in the both the K/BxN and CIA models suggests that
common pathological mechanisms (i.e., the influx of myeloid
derived cells of the innate immune system) exist that are being
targeted by SapC-DOPS. In total, our observations strongly
suggest that targeting arthritic joints using SapC-DOPS may have
far-reaching applicability in a variety of arthritic contexts.
The striking observation on arthritis-selective targeting of the
novel compound SapC-DOPS suggests that this molecule may be
used to detect inflammation in a variety of settings and contexts.
Studies directed at evaluating whether SapC-DOPS can detect
subclinical inflammation; other arthritides; and/or other inflam-
matory disorders remain to be performed; however, the results
presented here argue that SapC-DOPS facilitated imaging may be
used as a clinical parameter that could be highly valuable to assess
inflammatory joint disease. One of the advantages to SapC-DOPS
is its flexibility in incorporating other agents within the
nanovesicles and targeting inflammatory regions. This technology
also has the promising potential for specific delivery of agents to
joints, which would be beneficial particularly with respect to
therapies that when administered globally have undesirable side
effects.
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